Ginoden

Quick links to important sections

Ginoden

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Ginoden

Quick Facts

Property Description
Active Ingredients Ethinyl Estradiol, Gestodene
Form Oral Tablet
Pharmacological Class Combined Oral Contraceptive (COC)
Common Use Contraception (Birth Control)
Origin Synthetic (Steroidal Hormones)

What is Ginoden?

Ginoden: Identity and Pharmacological Classification

Ginoden is a specific brand of Combined Oral Contraceptive (COC), available as a prescription-only oral tablet. This medication manages fertility through the action of its synthetic hormone components. As a COC, Ginoden belongs to the larger class of combined hormonal contraceptives, distinguished by its fixed combination of estrogen and progestin, a category established for safety and efficacy.

Composition: Ethinyl Estradiol and Gestodene

The function of Ginoden derives from its status as a combination product containing two active ingredients: Ethinyl Estradiol (EE) and Gestodene (GSD). Ethinyl Estradiol functions as the synthetic estrogen component, while Gestodene is the synthetic progestin, often referenced as a third-generation derivative. This specific combination is widely used, with equivalent formulations appearing under other trade names like Femodene, Logest, and Minulet in various global markets. These synthetic progestins provide hormonal inhibition of fertility, supporting the product's use.

General Purpose and Contraceptive Principle

The primary purpose of Ginoden is to provide reliable contraception, or birth control, for women seeking to prevent unwanted pregnancy. This core benefit is achieved through the fundamental principle of suppression of ovulation, which is the primary antigonadotropic effect of the hormonal combination. By synthetically regulating the female reproductive cycle, the medicine creates a physiological environment unfavorable for conception, which is its core purpose as an oral contraceptive.

Regulatory References

  1. Contraception and Birth Control - NIH NICHD

What side effects are possible with Ginoden?

Possible Side Effects and Safety Information

The official safety profile for Ginoden, a combined oral contraceptive containing Ethinyl Estradiol and Gestodene, categorizes potential effects by their documented frequency and the affected System-Organ Class (SOC).

Adverse Reaction Frequencies

Adverse reactions are classified according to regulatory standards based on reported incidence:

  • Very Common (Affecting ge 1 in 10 users): Headache; breakthrough bleeding or spotting, particularly during the initial months of use.
  • Common (Affecting ge 1 in 100 users): Nausea, vomiting, abdominal pain; breast tenderness or pain; mood changes, including depression; dizziness; migraine; acne; and weight increase.
  • Uncommon (Affecting ge 1 in 1,000 users): Fluid retention, blood pressure elevation (Hypertension), decrease in libido, rash, and urticaria (hives).
  • Rare (Affecting ge 1 in 10,000 users): Venous Thromboembolism (VTE) and Arterial Thromboembolism (ATE); hypersensitivity reactions; and cholestatic jaundice.

Serious Adverse Reactions

Official regulatory documents emphasize the potential for Thromboembolic Events, which are rare but serious adverse reactions, including deep vein thrombosis, pulmonary embolism, myocardial infarction, and stroke. The risk of VTE is highest during the first year of initial use or upon re-initiating treatment after a break of four or more weeks. Additionally, the development of benign or malignant Hepatic Tumours is documented as a very rare but serious safety concern.

Population-Specific Safety Constraints

The safety profile includes specific limitations. The risk of serious cardiovascular events is officially documented to be increased for smokers and for women aged 35 years or older. Use is strictly restricted for individuals with a history of thromboembolic events, severe hepatic impairment or tumours, or a history of migraine with focal neurological symptoms (aura).

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory documents classify overdose scenarios for combined oral contraceptives like Ginoden (Ethinyl Estradiol and Gestodene) as generally not likely to be life-threatening. Reports indicate that there have been no documented serious ill effects resulting from oral contraceptive overdose, including accidental ingestion by children.


Documented Manifestations and Toxicity Profile

The clinical signs of overdose are primarily limited to non-severe symptoms that are consistent with the hormonal components. These may include nausea and vomiting as acute manifestations. In females, withdrawal bleeding or heavy vaginal bleeding may occur days after the overdose event. Other noted non-critical symptoms may be headache, breast tenderness, and emotional changes.


Emergency Actions and Management

Despite the low expected toxicity, it is a regulatory mandate to seek medical help right away upon suspected overdose. Individuals should contact a Poison Control Center or local emergency services immediately for assessment.

Management of Ginoden overdose relies on symptomatic and supportive treatment, as no specific antidote is known. Hospital monitoring, including vital signs and laboratory testing, may be implemented to manage symptoms and ensure stability.

Therapeutic Uses of Ginoden

What Ginoden Treats: Main Uses and Benefits

Ginoden is primarily indicated to support the prevention of pregnancy in women of childbearing age. The compound is utilized to manage the reproductive process through hormonal regulation.

Beyond this main purpose, the medication is used to support the regulation of the menstrual cycle. This is applied in clinical scenarios where there is a need to manage issues related to irregular bleeding or heavy menstrual flow. These supportive applications can help establish a more predictable monthly pattern. The medication is indicated for contraception and the supportive management of symptoms like dysmenorrhea (painful periods) and menorrhagia (heavy bleeding).


Quick Fact: Ginoden is utilized for Contraception and the Supportive Management of Menstrual Cycle Irregularities.

Regulatory References

  1. NIH MedlinePlus overview on combination oral contraceptives

Eligibility and Restrictions for Use

Ginoden is officially intended for females of reproductive potential seeking contraception. Use is permitted in post-menarche adolescents but is not indicated for elderly or postmenopausal women. Use is not recommended for women who are breastfeeding.

Populations for whom use is contraindicated

The medicine is absolutely contraindicated in individuals with:

Classification
Presence or history of thromboembolic disorders (e.g., DVT, PE, stroke, heart attack).
High cardiovascular risk factors, including smoking women over 35 years of age or migraine with aura.
Known or suspected breast cancer or other estrogen-dependent neoplasms.
Severe liver disease, liver tumors, or undiagnosed abnormal genital bleeding.
Pregnancy.

Eligibility-related restrictions

Use must be discontinued at least four weeks before and two weeks after major surgery involving prolonged immobilization. Postpartum initiation must be delayed until at least four weeks after delivery in women who are not breastfeeding. Eligibility is also constrained by specific conditions, such as uncontrolled hypertension or diabetes mellitus with vascular disease.

The official labeling defines eligibility by strictly excluding populations with an elevated risk of severe cardiovascular events or hormonal malignancies. The use of Ginoden is constrained by age, specific comorbidities, and physiological states, with pregnancy being an absolute contraindication.

What should I know about interactions with other medicines?

The official interaction profile for Ginoden, a Combined Oral Contraceptive (COC) containing Ethinyl Estradiol and Gestodene, is defined by documented modifications to the hormones' plasma concentrations due to co-administered substances.

Documented Pharmacokinetic Interactions

The primary mechanism of interaction involves the modulation of hepatic enzymes. This has two major regulatory consequences:

Interaction Type Examples of Interacting Medicines Regulatory Outcome
Enzyme Induction Rifampicin, Phenytoin, Carbamazepine, Phenobarbital, Primidone Decreased exposure of Ethinyl Estradiol and Gestodene, risking contraceptive failure.
Enzyme Inhibition Azole Antifungals, HIV/HCV Protease Inhibitors Increased exposure of the COC hormones, potentially increasing associated risks.

The herbal product St. John's Wort (Hypericum perforatum) is also documented as an enzyme inducer that can decrease contraceptive efficacy.

Contraindication and Pharmacodynamic Effects

Co-administration with specific Hepatitis C antiviral regimens, particularly combinations containing Ombitasvir, Paritaprevir, Ritonavir, or Dasabuvir, is formally contraindicated by regulatory bodies due to the documented risk of severe liver enzyme elevations (ALT).

Conversely, Ginoden's components are documented to reduce the plasma concentrations of certain co-administered drugs, such as Lamotrigine, which is related to the induction of its glucuronidation. Official documents also note that episodes of vomiting or severe diarrhea within four hours of administration may lead to reduced drug absorption.

These constraints establish mandatory requirements in the presence of co-administered medicines, determining when alternative precautions are necessary.

Mechanism of Action

Central Suppression of the HPO Axis (Primary Mechanism)

The medication's synthetic components, Ethinyl Estradiol (EE) and Gestodene (GSD), act as agonists on their respective Estrogen and Progesterone Receptors within the pituitary gland and hypothalamus. This receptor binding triggers an intense, artificial negative feedback signal that overrides the body’s natural cycle, resulting in the inhibition of Luteinizing Hormone (LH) and Follicle-Stimulating Hormone (FSH) release and leading directly to anovulation (the non-release of an egg).


Peripheral Barrier and Tissue Modulation (Secondary Mechanism)

The mechanism also involves peripheral action that supports the central effect. The progestin component, Gestodene, modulates the secretory function of the cervical glands, causing the mucus to become thick, highly viscous, and significantly impeding to sperm passage. Concurrently, the combination alters the structural state of the endometrium (uterine lining), resulting in a physiologically non-receptive state. This coordinated action is reinforced by EE, which induces the synthesis of Sex Hormone-Binding Globulin (SHBG).

Dosage and Administration Information

Ginoden is utilized in clinical practice solely through the oral route as a monophasic tablet containing a fixed dose of 0.075 mg Gestodene and 0.03 mg Ethinyl Estradiol. The standard dosing regimen is structured as a cyclic schedule intended for continuous long-term use.

The use pattern involves taking one active tablet daily for 21 consecutive days. This active period is consistently followed by a 7-day hormone-free interval (or a placebo pill interval for 28-day packs). To maintain the necessary hormonal consistency, the tablet must be consumed at approximately the same time each day, and is often taken after the evening meal or at bedtime to support adherence. New packs must be started immediately after the 7-day interval ends, ensuring the cycles continue unbroken for the duration the medication is used.

The initiation of Ginoden generally occurs on the first day of the natural menstrual cycle. Specific timing guidance exists for use following delivery, where the start is typically between 21 and 28 days post-partum.

Standard protocols include a protocol for timing disruption. If the tablet intake is delayed by more than 12 hours from the usual time, the last missed tablet is taken immediately, and additional, non-hormonal precautions are used for the subsequent seven consecutive days of active tablet taking. If severe gastrointestinal disturbance occurs shortly after intake, this event is procedurally managed as if a dose was missed.

Recent Clinical Evidence

Research evidence / Overview of studies for Ginoden


Evidence for use in Contraception (Prevention of Pregnancy)

The clinical evaluation of Ginoden (the Ethinyl Estradiol and Gestodene combination) was studied for outcomes related to pregnancy prevention primarily through large clinical evaluations. These studies monitored outcomes in healthy women of childbearing age, including those starting oral contraceptives. Since it is not ethical to conduct placebo-controlled trials for contraceptives, the medication was evaluated in prospective, non-comparative trials or comparative trials against other active birth control pills. Research examined the rate of unintended pregnancy, quantified using the Pearl Index. The findings describe patterns observed where the rates of unintended pregnancy was observed in specific ranges when the regimen was followed precisely. The results apply only to the populations studied and was associated with higher pregnancy rates in observational settings that reflect typical use due to factors like user compliance.


Evidence for the Supportive Management of Menstrual Cycle Symptoms

Beyond its main purpose, research examined the use of Combined Oral Contraceptives in managing conditions characterized by fluctuating manifestations related to the menstrual cycle. Studies explored outcomes related to physical discomfort, such as painful periods (dysmenorrhea), and was studied for outcomes related to menstrual predictability (cycle control). Evidence is limited for direct comparisons of this specific Gestodene/EE combination against all other therapeutic options for these supportive findings. Follow-up durations were limited in many symptom management studies, and research suggests the long-term changes or sustained effects of use are not fully established beyond the intermediate term.


What is Still Uncertain about Ginoden in Research

Research provides context but not individual predictions, and evidence highlights what is known—and what is still uncertain. One primary limitation noted in regulatory reviews is that the pregnancy rates observed in ideal clinical settings may not perfectly translate to evidence derived from settings with varying symptom burdens due to factors like user error. Furthermore, data related to pregnancy rates for this contraceptive class are extensive, but comparative evidence is lacking to definitively indicate different patterns or specific advantages of this Gestodene combination over other progestin/estrogen combinations. Research is ongoing to continually refine the understanding of how individual factors influence the observed patterns.

Key Studies & References

  1. Different combined oral contraceptives and the risk of venous thrombosis: systematic review and network meta-analysis
  2. CPMP PUBLIC ASSESSMENT REPORT Combined oral contraceptives and venous thromboembolism (Regulatory Review on Third Generation COCs including Gestodene)

Frequently Asked Questions (FAQ)

Common questions about Ginoden (FAQ)

Q: How quickly does Ginoden start working to prevent pregnancy?

A: Contraceptive protection is described as immediate when the first tablet is started on the first day of the natural menstrual period. If the tablet is started later in the cycle, official guidance suggests using a non-hormonal barrier method for the first 7 consecutive days of taking the active tablets to help ensure protection.

Q: Is it safe to drink alcohol while taking Ginoden?

A: Regulatory information documents a minor interaction between the estrogen component (Ethinyl Estradiol) and alcohol. Information regarding alcohol use while on this medication can be discussed with a healthcare professional.

Q: How long after stopping Ginoden will I be able to get pregnant?

A: Official health authority guidance indicates that a person’s fertility usually returns quickly after stopping a combined oral contraceptive. Evidence suggests most people who stop using the pill become pregnant within 12 months.

Q: Does Ginoden affect the results of blood tests?

A: Yes, official product information indicates that the active components may influence the results of certain laboratory tests. These can include tests for liver function, adrenal function, and parameters related to blood clotting (coagulation). Monitoring of these parameters via blood tests is sometimes advised by healthcare professionals.

Q: Will Ginoden help clear up acne?

A: Official documentation mentions that this combination may be used to help improve symptoms associated with Polycystic Ovary Syndrome (PCOS), including acne. The suitability and potential benefits for an individual's specific condition can be discussed with a healthcare provider.

Q: Is Ginoden associated with changes in hair growth?

A: Regulatory adverse reaction data documents that changes in hair growth are a possible effect of taking this medication. This can include both the loss of hair (alopecia) and the development of excessive hair (hirsutism).

Q: Will Ginoden cause my periods to stop completely?

A: Official adverse reactions data includes missed, absent, or irregular menstrual periods as possible effects of using this medication. If you experience a complete cessation of bleeding, it is described as a possible change while on the pill.

Q: Does Ginoden protect against sexually transmitted infections (STIs)?

A: No. Official safety information strictly clarifies that hormonal contraceptives do not provide protection against HIV/AIDS or other sexually transmitted infections (STIs). Non-hormonal barrier methods are needed for STI prevention.

Q: What happens if I accidentally take two Ginoden pills in one day?

A: Taking more than the recommended dose may potentially cause temporary symptoms such as nausea or vaginal bleeding. If two pills are taken to make up for a single missed dose, this action is generally consistent with the missed pill instructions.

Q: Does Ginoden have an effect on cholesterol levels?

A: Yes, the estrogen component (Ethinyl Estradiol) of the pill is known to affect lipid metabolism. Official documentation indicates that this may lead to changes in cholesterol and triglyceride levels.

Q: Can I skip my period by taking Ginoden continuously?

A: Health authority guidance notes that a healthcare professional may advise taking the active tablets continuously—skipping the hormone-free week—to intentionally delay or prevent withdrawal bleeding. This is a regimen that may be used, and it should be undertaken in consultation with a healthcare provider.

Q: Does official information clarify how Ginoden affects fertility after discontinuing use?

A: Yes, official health information clarifies that fertility typically returns to normal levels quickly after stopping the pill. Evidence suggests that most people who discontinue use become pregnant within 12 months, which is similar to the general population.

Q: Is Ginoden a suitable option for people with PCOS?

A: Official documentation mentions that this combination may be used to help improve various symptoms associated with Polycystic Ovary Syndrome (PCOS). The pill’s suitability for an individual’s specific condition is determined by a healthcare provider.

Q: What is Ginoden used for besides birth control?

A: According to official documentation, in addition to contraception, this medication may be used for purposes such as regulating irregular menstrual cycles and for the treatment of menorrhagia (heavy menstrual bleeding).

Q: Is Ginoden the same as other combination pills, or is there a difference?

A: Ginoden is a specific brand of Combined Oral Contraceptive that contains Gestodene, which is defined in clinical reviews as a third-generation synthetic progestin. This component has specific pharmacological characteristics that provide differences in metabolism compared to older progestins.

Q: What happens if I forget to start a new pack of Ginoden on time?

A: If you forget to start a new pack after the 7-day break, official health guidance states you should immediately take the most recent missed pill and start the new pack right away. Non-hormonal backup contraception is suggested for the next 7 consecutive days.

Q: Do studies show that Ginoden is effective for heavy periods?

A: Yes, official documentation explicitly lists the use of this combined oral contraceptive for the treatment of menorrhagia (severe blood loss during a period). Research related to this use focuses on reducing the volume of menstrual flow.

Q: Why is Ginoden sometimes prescribed for conditions other than contraception?

A: It is sometimes prescribed for its effect on regulating the menstrual cycle. Specifically, this is to help manage menorrhagia (heavy menstrual bleeding) and correct highly irregular cycles.

Q: Are there specific symptoms that require immediate medical attention while taking Ginoden?

A: Yes. Official patient information lists specific symptoms that require immediate medical care as they may indicate a serious adverse reaction, such as a blood clot. These symptoms include sudden changes in vision, sudden severe headache, or shortness of breath.

Q: Is the nausea I feel when starting Ginoden temporary?

A: Nausea is listed as a common side effect when using this medication. Patient information often suggests that common side effects are most noticeable when starting the pill and typically lessen or resolve over time.

Q: Are there any documented long-term effects of using Ginoden for many years?

A: Official reviews of combined oral contraceptives indicate a potential link between long-term use and an increased risk of certain conditions, such as breast cancer, in specific patient subgroups. These risks are carefully balanced against the benefits and should be discussed with a doctor.

Q: Can Ginoden cause changes to my skin or vision?

A: Yes, regulatory data documents that changes to the skin and vision are possible adverse reactions. Skin changes include rash or yellowing, and vision changes include sudden changes or difficulty wearing contact lenses.

Q: What is the difference in hormone type between Ginoden and Pills X and Y?

A: This pill contains the synthetic progestin Gestodene, which is classified as a third-generation derivative. This classification differentiates it pharmacologically due to Gestodene’s specific characteristics that provide differences in metabolism compared to older progestins.

How should Ginoden be stored and disposed of?

Storage and Disposal Instructions for Ginoden

Ginoden (Ethinyl Estradiol and Gestodene) must be stored under specific, officially mandated conditions to ensure its stability and labeled shelf-life.

Official Storage Requirements

Condition Requirement
Temperature Limit Do not store above 25°C or 30°C, depending on the specific regulatory approval for the formulation.
Environmental Protection Must be protected from light and moisture.
Container Keep the product in its original package.
Child Safety Store securely, out of the sight and reach of children.

Disposal of Unused Product

Unused or expired Ginoden must not be disposed of via household waste or wastewater. Disposal must be carried out in accordance with local and national pharmaceutical waste collection requirements to protect the environment, as stated in regulatory guidelines.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Ginoden found in:

A-Z Index: